A safety study of KAN-101 in patients with celiac disease. The study has two parts: 1. Part A - first in human study in which patients receive a single dose of KAN-101 2. Part B - patients will receive three doses of either KAN-101 or placebo
Study KAN-101-01 is a Phase 1, FIH study designed to evaluate the safety and tolerability of KAN-101 in patients with celiac disease on a gluten free diet (GFD). An overview of the two parts and proposed dose groups is given below: 1. Part A (SAD): Patients will receive a single dose of KAN-101. 2. Part B (MAD): Patients will receive three doses of either KAN-101 or placebo.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Enrollment
41
Anaheim Clinical Trials
Anaheim, California, United States
Diablo Clinical Research
Walnut Creek, California, United States
Innovative Medical Research of South Florida
Aventura, Florida, United States
Incidence and Severity of Treatment-emergent Adverse Events (TEAEs)
Incidence and severity of treatment-emergent adverse events (TEAEs) as assessed by the Common Terminology Criteria for Adverse Events (CTCAE) v5.0 or higher
Time frame: Up to 28 Days
Cmax
Geometric mean of maximum drug concentration (Cmax)
Time frame: 0, 7, 15, 30, 60, 120, 180, 240, 300, 360 minutes post dose on Days 1 and and 7
AUC Last
Area under the plasma concentration-time curve from time 0 to the last measurable time point (AUC last)
Time frame: 0, 7, 15, 30, 60, 120, 180, 240, 300, 360 minutes post dose on Days 1 and and 7
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
GCP Research
St. Petersburg, Florida, United States
Tandem Clinical Research
Marrero, Louisiana, United States
Parexel International- EPCU Baltimore
Baltimore, Maryland, United States
West Michigan Clinical Research Center
Wyoming, Michigan, United States
Mayo Clinic
Rochester, Minnesota, United States
Celiac Disease Center at Columbia University
New York, New York, United States
North Carolina Clinical Research
Raleigh, North Carolina, United States
...and 3 more locations